Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors

The pCR was more frequently observed in HER2 overexpression type and Triple negative type of breast cancer. That could achieve a higher rate of pCR on paclitaxel class joint anthracycline-based chemotherapy. But Triple negative type showed worse prognosis, due to residual tumor after neoadjuvant chemotherapy, which could be in combination or sequential, at the neoadjuvant / adjuvant setting (NCCN 2016 Breast cancer, chemotherapy regimens), So how to choose a more appropriate neoadjuvant chemotherapy regimens, we should need further research.